Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.48 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | POLG | P54098 | 2/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20879485 | 1.00 | PDE3A (0.48) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL20879387 | 0.93 | LMNA (0.52) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL18877436 | 0.90 | PDE3A (0.49) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL22110711 | 0.89 | PDE3A (0.48) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL30997061 | 0.89 | PDE3A (0.48) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL25399556 | 0.89 | PDE3A (0.48) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL20879508 | 0.89 | PDE3A (0.48) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL25401300 | 0.88 | PDE3A (0.46) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL26793921 | 0.88 | PDE3A (0.46) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL25401505 | 0.87 | PDE3A (0.47) | PDE3ALMNACACNA1FALBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-12187758-B2 | Compounds and methods for treating disease | ROME THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023192499-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | PRIMEFOUR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2022256625-A1 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | TRANSPOSON THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| EP-3797782-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | Janssen BioPharma, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-3160476-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTION | JANSSEN BIOPHARMA INC (US) | 2020-09-30 | — | — | EP | disclosed |
| WO-2015200219-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | PDE3A 4016/4885LMNA 2032/4885CACNA1F 1035/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | PDE3A 4016/4885LMNA 2032/4885CACNA1F 1035/4885 |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | TYMP, TYMS, DCTD | PDE3A 2953/4885LMNA 3687/4885CACNA1F 4304/4885 |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | UNG, OGG1, NTPCR | PDE3A 1349/4885LMNA 1053/4885CACNA1F 4773/4885 |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | PDE3A 4016/4885LMNA 2032/4885CACNA1F 1035/4885 |
| US-12187758-B2 | Compounds and methods for treating disease | EHMT1, POLRMT, RNASE1 | PDE3A 4016/4885LMNA 2032/4885CACNA1F 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.